Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 3677.06 points, down by 0.17%, while the total trading volume reached 1,893.89 billion yuan, indicating a mixed performance among stocks breaking through the annual line [1] Group 1: Market Performance - As of 13:59 today, the Shanghai Composite Index is at 3677.06 points, with a decrease of 0.17% [1] - The total trading volume of A-shares today is 1,893.89 billion yuan [1] Group 2: Stocks Breaking Through Annual Line - A total of 16 A-shares have surpassed the annual line today, with notable stocks including *ST Xin Yuan, *ST Hua Rong, and Meihao Medical, showing significant deviation rates of 5.64%, 4.40%, and 2.63% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Zhongke Ruankai, Tianwei Food, and Yongzhen Co., with minimal deviation percentages [1] Group 3: Deviation Rate Rankings - The top three stocks with the highest deviation rates are: - *ST Xin Yuan: 12.87% increase, 14.89% turnover rate, annual line at 6.06 yuan, latest price at 6.40 yuan, deviation rate of 5.64% [1] - *ST Hua Rong: 4.94% increase, 0.45% turnover rate, annual line at 7.12 yuan, latest price at 7.43 yuan, deviation rate of 4.40% [1] - Meihao Medical: 2.76% increase, 12.60% turnover rate, annual line at 20.34 yuan, latest price at 20.88 yuan, deviation rate of 2.63% [1]

Company Overview - Meihao Medical closed at 20.32 yuan, down 1.41%, with a rolling PE ratio of 32.32 times and a total market value of 11.559 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 57.48 times and a median of 40.95 times [1] - As of August 8, 2025, Meihao Medical had 15,790 shareholders, an increase of 2,605 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home ventilator components, cochlear implant components, other medical product components, precision molds, automation equipment, and home and consumer electronics components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, a year-on-year increase of 5.05% [1] - The net profit for the same period was 51.875 million yuan, reflecting a year-on-year decrease of 10.62% [1] - The sales gross margin stood at 39.28% [1]

Group 1 - The core point of the news is that Meihao Medical has seen significant financing activity, with a net buy of 5.3963 million yuan on August 12, 2023, indicating investor interest in the company [1] - Over the last three trading days from August 8 to August 12, Meihao Medical received financing purchases of 4.3 million yuan, 3.4 million yuan, and 3.4 million yuan respectively, showing a consistent trend in financing inflow [1] - On the same day, the company had a financing repayment amount of 2.9 million yuan, which reflects the ongoing trading dynamics in the market [1] Group 2 - In terms of securities lending, on the same day, Meihao Medical had a short selling of 50 shares and a net purchase of 390 shares, indicating a mixed sentiment among investors regarding the stock [2]

证券之星消息，截至2025年8月12日收盘，美好医疗(301363)报收于20.61元，上涨1.13%，换手率 11.99%，成交量18.73万手，成交额3.89亿元。 8月12日的资金流向数据方面，主力资金净流入4124.51万元，占总成交额10.61%，游资资金净流入 649.83万元，占总成交额1.67%，散户资金净流出4774.34万元，占总成交额12.28%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： | 指标 | 美好医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 117.24亿元 | 120.28亿元 | 33 123 | | 净资产 | 35.22亿元 | 38.99亿元 | 44 123 | | 净利润 | 5187.5万元 | 7927.36万元 | 41 123 | | 市盈率(动) | 56.5 | 69.5 | 57 123 | | 市净率 | 3.37 | 3.99 | 69 123 | | 毛利率 | 39.28% | 51.34% | 87 123 | | 净利率 | 17.54% | 10.8 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 20.61 yuan with a PE ratio of 32.79, marking a 50-day low, and a total market capitalization of 11.724 billion yuan [1][2] - In terms of industry comparison, the average PE ratio for the medical device industry is 57.51, with a median of 41.25, positioning Meihao Medical at the 63rd rank within the industry [1][2] - The company has seen a net inflow of 41.2451 million yuan in principal funds on August 12, with a total inflow of 80.4884 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest financial report for Q1 2025 shows that the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Market Overview - The medical device sector rose by 1.16% on August 12, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3665.92, up 0.5%, while the Shenzhen Component Index closed at 11351.63, up 0.53% [1] Top Gainers in Medical Device Sector - Mai Lande (688273) closed at 52.83, up 18.06%, with a trading volume of 150,500 shares and a transaction value of 771 million [1] - Sanxin Medical (300453) closed at 10.75, up 14.24%, with a trading volume of 810,000 shares [1] - Xiangyu Medical (688626) closed at 64.40, up 11.02%, with a trading volume of 102,800 shares [1] - Maipu Medical (301033) closed at 88.80, up 10.38%, with a trading volume of 24,000 shares [1] - Ruimaite (301367) closed at 97.77, up 6.63%, with a trading volume of 33,200 shares [1] Decliners in Medical Device Sector - Kehua Bio (002022) closed at 7.58, down 3.44%, with a trading volume of 417,400 shares [2] - Yirui Bio (300942) closed at 12.91, down 2.93%, with a trading volume of 104,400 shares [2] - Rendu Bio (688193) closed at 51.64, down 2.68%, with a trading volume of 8,204 shares [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 730 million from institutional investors, while retail investors saw a net inflow of 112 million [2] - The top stocks with significant net inflows from retail investors include Yirui Medical and Mai Lande, while major outflows were observed in stocks like Aiyu Technology and Meihua Medical [3]

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 was held on August 11, 2025 [2] - The meeting approved the proposal regarding the adjustment of the expected guarantee amount for the company and its subsidiaries [2]

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-11 | 20.38 1.75% | | -1019.91万 | -2.74% | 967.77万 | 2.60% | 52.14万 | - 0.14% | | 2025-08-08 | 20.03 | 7.17% | 5599.57万 | 11.04% | 2231.77万 | 4.40% | -7831.34万 | -15.44% | | 2025-08-07 | 18.69 -0.48% | | -597.21万 | -3.98% | 304.23万 | 2.03% | 292.99万 | 1.95% | | 2025-08-06 | 18.78 -0.27% | | -58.12万 | -0.73% | -139.02万 | -1.74% | 197.14万 | 2.47% | | 2025-08-05 | 18.83 0. ...

8月11日，美好医疗今日收盘20.38元，上涨1.75%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到32.42倍，创49天以来新低，总市值115.94亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.56倍，行业中值39.76倍，美好医疗排 名第64位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.96亿元，同比5.05%；净利润5187.50万元，同 比-10.62%，销售毛利率39.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗32.4231.873.29115.94亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德 ...

法律意见书 中国 深圳 福田区 益田路6001号太平金融大厦11、12楼 邮政编码：518038 11F/12F., Taiping Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P.R. China 518038 电话(Tel.)：（0755）8826 5288 传真（Fax.）：（0755）8826 5537 网址（Website）：https://www.sundiallawfirm.com 广东信达律师事务所 关于深圳市美好创亿医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 信达会字（2025）第 237 号 致：深圳市美好创亿医疗科技股份有限公司 广东信达律师事务所（以下简称"信达"）接受深圳市美好创亿医疗科技股 份有限公司（以下简称"贵公司"）的委托，指派律师参加了贵公司二〇二五年 第一次临时股东大会（以下简称"本次股东大会"），并进行了必要的验证工作。 现根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股 东会规则》（以下简称"《股东会规则》"）以及贵公司《公司章程》的规定， 按照律师 ...